Find a Trial

Trial Summary


Protocol No.CTO-20180101
StatusOPEN TO ACCRUAL
Principal InvestigatorAdra, Nabil
ScopeNational
PhasePhase I
Age GroupAdult
TitleA Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer
DescriptionA study to evaluate the safety and tolerability of AMG 160 in adult subjects with metastatic castration-resistant prostate cancer (mCRPC), and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • Total serum testosterone less than/equal to 50 ng/dL or 1.7 nmol/L.
  • Subject should have undergone bilateral orchiectomy or should be on continuous androgen-deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) agonist or antagonist.
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesProstate
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632
    Email: iutrials@iu.edu